BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17723177)

  • 1. From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
    Zhou GB; Li G; Chen SJ; Chen Z
    Acta Pharmacol Sin; 2007 Sep; 28(9):1434-49. PubMed ID: 17723177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
    Chen SJ; Zhou GB
    IUBMB Life; 2012 Aug; 64(8):671-5. PubMed ID: 22714999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemia, an effective model for chemical biology and target therapy.
    Chen GQ; Wang LS; Wu YL; Yu Y
    Acta Pharmacol Sin; 2007 Sep; 28(9):1316-24. PubMed ID: 17723165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular targets and the treatment of myeloid leukemia.
    Ikeda A; Shankar DB; Watanabe M; Tamanoi F; Moore TB; Sakamoto KM
    Mol Genet Metab; 2006 Jul; 88(3):216-24. PubMed ID: 16678459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.
    Hu J; Zhou GB; Wang ZY; Chen SJ; Chen Z
    Adv Cancer Res; 2007; 98():191-220. PubMed ID: 17433911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
    Vitoux D; Nasr R; de The H
    Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
    Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based therapy for leukemia: a lesson from ATRA therapy.
    Naoe T
    Nagoya J Med Sci; 2001 Nov; 64(3-4):103-8. PubMed ID: 11820331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment concepts of acute promyelocytic leukemia.
    Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expanding role of arsenic in acute promyelocytic leukemia.
    Tallman MS
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current clinical trials using new targeted therapies for myeloid leukemia and the research trends].
    Ishizawa J; Saya H
    Nihon Rinsho; 2009 Oct; 67(10):1932-7. PubMed ID: 19860193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Arsenic treatment for leukemia: new model of human cancer target treatment].
    Zhao WW; Chen SJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):439-40. PubMed ID: 15854545
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute promyelocytic leukemia: recent advances in diagnosis and management.
    Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
    Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
    Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
    Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid receptors, hematopoiesis and leukemogenesis.
    Collins SJ
    Curr Opin Hematol; 2008 Jul; 15(4):346-51. PubMed ID: 18536573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Soverini S; Martinelli G; Iacobucci I; Baccarani M
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic compounds: revived ancient remedies in the fight against human malignancies.
    Liu JX; Zhou GB; Chen SJ; Chen Z
    Curr Opin Chem Biol; 2012 Apr; 16(1-2):92-8. PubMed ID: 22342767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.